EUVIMEDEUVIMED entdecken
Crossref

Radio-Biological Enhancement of an Interleukin-6 Receptor Antibody by the β-Particle-Emitting Radionuclide Iodine-131 in Multiple Myeloma

Hiroki Goto, Yujiro Ueda, Mariko Takano, Prin Sungwan, Yoshioki Shiraishi, Koki Hasegawa, Seiji Okada

Biological and Pharmaceutical Bulletin · 2026

DOI: 10.1248/bpb.b26-00269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2026. Verfasst von Hiroki Goto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radioisotope and Tumor Pathobiology, Institute of Resource Development and Analysis, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto …. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Multiple Myeloma, Radioimmunotherapy, Receptors, Interleukin-6. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) is a hematologic malignancy defined by the accumulation of neoplastic plasma cells in the bone marrow. Although novel therapies have improved outcomes in patients with MM, most cases eventually relapse and become refractory, highlighting the need for new therapeutic strategies. Interleukin-6 (IL-6) plays a key role in MM progression by promoting tumor cell growth and survival. It promotes the growth of IL-6-dependent MM cells, and inhibition of IL-6 signaling could suppress their proliferation. However, the efficacy of the anti-IL-6 receptor antibody (Ab) tocilizumab (Toc) appears to be limited in IL-6-independent cases, and its clinical application has not yet been established. To enhance the therapeutic efficacy of Toc, an iodine-131 (131I)-labeled Toc was evaluated as a β-emitting radioimmunotherapy (RIT), which combines Ab specificity with the cytotoxicity of radionuclides to deliver targeted radiation to MM cells. In vitro assays demonstrated that the 131I-labeled Toc induced growth inhibition in both IL-6-responsive and IL-6-irresponsive MM cells. Furthermore, biodistribution studies and therapeutic evaluation in an MM xenograft mouse model revealed selective tumor accumulation and significant tumor growth suppression following intraperitoneal administration. These findings suggest that 131I labeling enhances the antitumor activity of Toc and may overcome the limitations of Toc monotherapy. Therefore, β-emitting RIT using 131I represents a promising strategy for MM, and further investigation into its mechanistic details is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iodine RadioisotopesMultiple MyelomaRadioimmunotherapyReceptors, Interleukin-6Antibodies, Monoclonal, HumanizedBeta ParticlesAnimalsHumansCell Line, TumorInterleukin-6FemaleTissue DistributionMiceXenograft Model Antitumor AssaysMice, SCID

Stichwörter der Autor:innen

interleukin-6 receptoriodine-131multiple myelomaradioimmunotherapytocilizumabxenograft model

Substanzen

Iodine RadioisotopesReceptors, Interleukin-6Antibodies, Monoclonal, HumanizedIodine-131tocilizumabInterleukin-6

Autor:innen und Institutionen

  • Division of Radioisotope and Tumor Pathobiology, Institute of Resource Development and Analysis, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan.
  • Radioisotope Center, Institute of Resource Development and Analysis, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan.
  • Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan.
  • Department of Radiological Sciences, School of Health Sciences, Fukushima Medical University, 10-6 Sakaemachi, Fukushima 960-8516, Japan.

Zitieren

APA

Goto, H., Ueda, Y., Takano, M., Sungwan, P., Shiraishi, Y., Hasegawa, K., & Okada, S. (2026). Radio-Biological Enhancement of an Interleukin-6 Receptor Antibody by the β-Particle-Emitting Radionuclide Iodine-131 in Multiple Myeloma. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b26-00269

Vancouver

Goto H, Ueda Y, Takano M, Sungwan P, Shiraishi Y, Hasegawa K, et al. Radio-Biological Enhancement of an Interleukin-6 Receptor Antibody by the β-Particle-Emitting Radionuclide Iodine-131 in Multiple Myeloma. Biological and Pharmaceutical Bulletin. 2026. doi:10.1248/bpb.b26-00269

BibTeX
@article{Goto2026,
  author = {Goto, Hiroki and Ueda, Yujiro and Takano, Mariko and Sungwan, Prin and Shiraishi, Yoshioki and Hasegawa, Koki and Okada, Seiji},
  title = {Radio-Biological Enhancement of an Interleukin-6 Receptor Antibody by the β-Particle-Emitting Radionuclide Iodine-131 in Multiple Myeloma},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2026},
  doi = {10.1248/bpb.b26-00269}
}
Kostenlos starten →